Speciality Medicines Ltd (SPML) — shareholding pattern, promoter holding, financials and share price
About Speciality Medicines Ltd (SPML)
Speciality Medicines Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SPML and on the BSE under scrip code 544738. Its ISIN is INE0R0M01014.
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals. [1]
Listed peers in Pharmaceuticals: Accretion Pharmaceuticals Ltd, Parnax Lab Ltd, Bio Medica Laboratories Ltd, Panchsheel Organics Ltd, Auro Laboratories Ltd, Quest Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹183.5 a share on 10 Jul 2026, Speciality Medicines Ltd (SPML) was valued at a price-to-earnings ratio of 12.37x against an industry P/E of 36.41x and a price-to-book of 2.26x on a book value of ₹81.04 per share. Solomo computes return on equity of 18.31% and return on capital employed of 18.42% from filed results.
- P/E
- 12.37x
- Industry P/E
- 36.41x
- P/B
- 2.26x
- EPS (TTM)
- ₹14.1
- Book value / share
- ₹81.04
- ROE
- 18.31%
- ROCE
- 18.42%
- ROA
- 13.68%
- Debt / equity
- 0.09x
- Dividend yield
- 0%
- EBITDA margin
- 19.27%
- 52-week range
- ₹183 – ₹183.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2023In the year ended Mar 2023, Speciality Medicines Ltd (SPML) reported revenue of ₹23.18 crore, net profit of ₹1.7 crore and earnings per share of ₹4.45. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹45 crore and net profit ₹8 crore (standalone).
| Metric | Mar 2023 |
|---|---|
| Revenue (₹ cr) | 23.18 |
| Net profit (₹ cr) | 1.7 |
| EPS (₹) | 4.45 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 12.95% | 111.74% |
| Profit growth | 79.86% | 193.86% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 43.43% of Speciality Medicines Ltd (SPML), foreign institutional investors (FII) hold 0.24%. Market capitalisation was ₹161 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Mar 2026: APARNA SAMIR THAKKER 7.33%, JIGNESH RAJENDRA DESAI 5.44%, HUF 4.1%, YASH HITESH PATEL 2.28%, AIKYAM CAPITAL PRIVATE LIMITED 1.71%, Market Maker 1.71%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 43.43% | - | 0.24% | - | 56.57% |